Hirakawa K - Search Results

1

Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.

Morita S, Ohashi Y, Hirakawa K, Nakata B, Saji S, Sakamoto J. Morita S, et al. Among authors: hirakawa k. Jpn J Clin Oncol. 2004 Mar;34(3):159-61. doi: 10.1093/jjco/hyh031. Jpn J Clin Oncol. 2004. PMID: 15078913 Clinical Trial.

2

Prognostic value of microsatellite instability in resectable pancreatic cancer.

Nakata B, Wang YQ, Yashiro M, Nishioka N, Tanaka H, Ohira M, Ishikawa T, Nishino H, Hirakawa K. Nakata B, et al. Among authors: hirakawa k. Clin Cancer Res. 2002 Aug;8(8):2536-40. Clin Cancer Res. 2002. PMID: 12171881

3

Genetic alterations in adenoma-carcinoma sequencing of intraductal papillary-mucinous neoplasm of the pancreas.

Nakata B, Yashiro M, Nishioka N, Aya M, Yamada S, Takenaka C, Ohira M, Ishikawa T, Nishino H, Wakasa K, Hirakawa K. Nakata B, et al. Among authors: hirakawa k. Int J Oncol. 2002 Nov;21(5):1067-72. Int J Oncol. 2002. PMID: 12370756

4

Very low incidence of microsatellite instability in intraductal papillary-mucinous neoplasm of the pancreas.

Nakata B, Yashiro M, Nishioka N, Aya M, Yamada S, Takenaka C, Ohira M, Ishikawa T, Nishino H, Wakasa K, Seki S, Hirakawa K. Nakata B, et al. Among authors: hirakawa k. Int J Cancer. 2002 Dec 20;102(6):655-9. doi: 10.1002/ijc.10771. Int J Cancer. 2002. PMID: 12448010

5

Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients.

Nakata B, Wang YQ, Yashiro M, Ohira M, Ishikawa T, Nishino H, Seki S, Hirakawa K. Nakata B, et al. Among authors: hirakawa k. Oncol Rep. 2003 Jul-Aug;10(4):997-1000. Oncol Rep. 2003. PMID: 12792759

6

Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer.

Ogawa Y, Ishikawa T, Chung SH, Ikeda K, Takashima T, Onoda N, Nakata B, Nishiguchi Y, Hirakawa K. Ogawa Y, et al. Among authors: hirakawa k. Anticancer Res. 2003 Jul-Aug;23(4):3453-7. Anticancer Res. 2003. PMID: 12926089 Clinical Trial.

7

Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.

Matsunaga N, Yamada N, Ohira M, Tachimori A, Nishiguchi Y, Nishino H, Seki S, Hirakawa K. Matsunaga N, et al. Among authors: hirakawa k. Oncol Rep. 2004 Jan;11(1):167-71. Oncol Rep. 2004. PMID: 14654921

8

Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.

Nakata B, Muguruma K, Yamagata S, Yukimoto K, Maeda K, Nishiguchi Y, Ohira M, Kato Y, Hirakawa K. Nakata B, et al. Among authors: hirakawa k. Dig Dis Sci. 2004 Jan;49(1):60-4. doi: 10.1023/b:ddas.0000011603.40133.f9. Dig Dis Sci. 2004. PMID: 14992436

9

[A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum].

Takashima T, Yamagata S, Fukunaga S, Inoue T, Yashiro M, Nakata B, Nishiguchi Y, Kato Y, Ohira M, Ishikawa T, Hirakawa K. Takashima T, et al. Among authors: hirakawa k. Gan To Kagaku Ryoho. 2004 Feb;31(2):247-50. Gan To Kagaku Ryoho. 2004. PMID: 14997761 Japanese.

10

Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902).

Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, Hirakawa K. Nakata B, et al. Among authors: hirakawa k. Clin Cancer Res. 2004 Mar 1;10(5):1664-9. doi: 10.1158/1078-0432.ccr-03-0045. Clin Cancer Res. 2004. PMID: 15014017 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,473 results

Search Page

Filters